Dexcom reported $4.97B of revenue over the trailing twelve months, +16% on the year before. 11 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $4.97B (to Q2 2026). Net income: $1000M, trailing twelve months to Q2 2026. Free cash flow: $1.41B, trailing twelve months to Q2 2026. Operating margin: 23%, trailing twelve months to Q2 2026.

DXCMDexcom

Healthcare

$84.10+11% 1Y

$84.10

$54.8452 weeks$92.35

DXCM as reported

Dexcom reported $4.97B of revenue over the trailing twelve months, +16% on the year before. 11 reported series are charted on this page, each one as filed.

$4.97B

Revenue, trailing twelve months · to Q2 2026 · +16% against the twelve months before

Net income: $1000M
Net income · +75% year on year · trailing twelve months to Q2 2026
Free cash flow: $1.41B
Free cash flow · +146% year on year · trailing twelve months to Q2 2026
Operating margin: 23%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for DXCM, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$4.97B	+16%	Q2 2026
Net income	$1000M	+75%	Q2 2026
EPS	$2.52	+75%	Q2 2026
Gross margin	62%	n/a	Q2 2026
Operating margin	23%	n/a	Q2 2026
Net margin	20%	n/a	Q2 2026
ROE	32%	n/a	Q2 2026
ROA	13%	n/a	Q2 2026
ROIC	23%	n/a	Q3 2018 · 31 quarters behind
Free cash flow	$1.41B	+146%	Q2 2026
P/E	33.4	n/a	today

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.